TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: An Efficacy and Safety Study of Telaprevir in Patients With Genotype 1 Hepatitis C Infection After Liver Transplantation

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* First time liver transplant recipient whose primary pre-transplant diagnosis was chronic hepatitis C genotype 1~* More than 6 months to 10 years post-liver transplant~* Patient did or did not receive treatment for HCV prior to liver transplantation~* Patient must agree to have a liver graft biopsy during the screening period unless they had a biopsy within three months of the screening period (for patients between 6 months and one year post transplant) or within six months of the screening period (for patients who are more than one year post transplant)~* A female patient of childbearing potential and a nonvasectomized male patient who has a female partner of childbearing potential must agree to the use of 2 effective methods of birth control from screening until 6 months (female patient) or 7 months (male patient) after the last dose of ribavirin~Exclusion Criteria:~* Patient is currently infected or co-infected with HCV of another genotype than genotype 1~* Patient received treatment for hepatitis C following liver transplantation~* Patient has history of decompensated liver disease or shows evidence of significant liver disease in addition to hepatitis C~* Patient with human immunodeficiency virus or hepatitis B virus co-infection~* Patient with active malignant disease or history of malignant disease within the past 5 years (with the exception of treated basal cell carcinoma or hepatocellular carcinoma)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Telaprevir+Peg-IFN-alfa-2a+Ribavirin (Type: EXPERIMENTAL): Patients will be treated for 12 weeks with telaprevir in combination with Pegylated interferon alfa-2a (Peg-IFN-alfa-2a) and ribavirin followed by 36 weeks of treatment with Peg-IFN-alfa-2a and ribavirin alone.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Arginase Inhibition in Ischemia-reperfusion Injury

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Coronary artery disease~Exclusion Criteria:~* Age \>80 years, Myocardial infarction/unstable angina within 6 weeks prior to the study, Raynaud's phenomenon, peripheral vasculopathies, arterial shunting or other vascular surgery of the study arm, Any concomitant disease or condition that may interfere with the possibility for the patient to comply with or complete the study protocol, Participant in an ongoing study, Unwillingness to participate following oral and written information.

- Gender: MALE
- Minimum Age: None
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- N-hydroxy-nor-arginine (Type: EXPERIMENTAL): N-hydroxy-nor-arginine 0.1 mg/ min i.a. for 20 min
- NaCl (Type: PLACEBO_COMPARATOR): NaCl 0.9%, 6 ml/min i.a. for 20 min

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Glimepiride as Oral Anti-Diabetic (OAD) Initiation Mono-therapy in Chinese Type 2 Diabetes Mellitus (T2DM)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Newly diagnosed T2DM and inadequately controlled with diet and exercise or T2DM diagnosed \<6 months and who had not taken oral antidiabetic medication or insulin for \>3months.~* HbA1C more than 7.5 and less than 11.~Exclusion Criteria:~* Fasting plasma glucose of \>13.5mmol/L~* Type 1 Diabetes Mellitus (T1DM)~* Patient with acute illness hospitalized in last 2 months~* Patient with active liver disease, impaired renal or hepatic functions~* Known hypersensitivity to glimepiride, other sulfonylureas, other sulfonamides or any other excipients of AMARYL~* Pregnant and lactating women~The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): The treatment period is 16 weeks with 5 visits: at weeks 2, 4, 8, 12, 16. At every visit if Fasting Blood Glucose (FBG) \>7.0mmol/L the Glimepiride dosage is increased from 1mg to 2mg or 2mg to 4mg.~At every visit if FBG\<3.9mmol/L the Glimepiride dosage is decreased from 4mg to 2mg or 2mg to 1mg.~Patients who have been on 4mg for 4 weeks and FBG\>11.0mmol/L at visit, another treatment can be added at the physician's discretion.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Treating Pyelonephritis an Urosepsis With Pivmecillinam

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* E.coli in blood culture~* AND identical isolate in urine sample (\>= 1.000 CFU) OR relevant clinical signs of UTI~Exclusion Criteria:~* Bacterial infection origin from another organ (e.g. pneumonia)~* Severe sepsis with multiorgan failure~* Perinephritic abscess~* Pyonephrosis requiring drainage~* Allergy to pivmecillinam~* E.coli isolate resistant to pivmecillinam~* Pregnancy/breastfeeding~* Severe neutropenia~* Prostatitis~* Severe kidney failure (eGFR\<15 ml/min)~* Using valproate

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 110 Years
- Healthy Volunteers: f

Study Arms:
- Pivmecillinam (Type: EXPERIMENTAL): Patients treated with pivmecillinam

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety Study of ESBA1008 Versus EYLEA®

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Give written informed consent; be able to make the required study visits and follow instructions.~* Diagnosis of wet age-related macular degeneration, as specified in protocol.~* Best-corrected visual acuity (BCVA) as specified in protocol~* Other protocol-specified inclusion criteria may apply.~Exclusion Criteria:~* Either eye: Any active ocular or periocular infection or active intraocular inflammation.~* Study eye: Any approved or investigational treatment for exudative AMD other than vitamin supplements.~* Study eye: Any current or history of macular or retinal disease other than exudative AMD.~* Study eye: Any concurrent intraocular condition that, in the opinion of the Investigator, could require medical or surgical intervention during the course of the study to prevent or treat vision loss, or that limits the potential to gain visual acuity with the investigational product.~* Study eye: Uncontrolled glaucoma.~* Study eye: Any ocular disease that, in the opinion of the Investigator, could compromise the visual acuity.~* Study eye: History of eye surgery, as specified in protocol.~* Study eye: Use of corticosteroids, as specified in protocol.~* Any medical condition that, in the opinion of the Investigator, would preclude scheduled study visits, completion of the study or safe administration of investigational product.~* Any screening laboratory result that, in the opinion of the Investigator, would make the patient unsuitable for study participation.~* History of hypersensitivity to any component used in the study, as assessed by the Investigator.~* Women of childbearing potential: Lactating, pregnant, plan to become pregnant, or not using adequate birth control, as specified in protocol.~* Participation in an investigational drug or device study within time period specified in protocol.~* Other protocol-defined exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- ESBA1008 (Type: EXPERIMENTAL): ESBA1008 solution, 7 intravitreal (IVT) injections, as specified in protocol
- EYLEA (Type: ACTIVE_COMPARATOR): Aflibercept, 8 intravitreal (IVT) injections, as specified in protocol

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Hydrocortisone Replacement in Patients With Secondary Adrenal Insufficiency (SUPREME CORT)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with secondary adrenal insufficiency.~* Age ≥ 18 - 75 years~* ≥ One year after tumor treatment with surgery and/or radiotherapy~* On stable concomitant medications for at least six months prior to entry of study~* Body weight 50-100 kg~Exclusion Criteria:~* Inability of legal consent~* Documented cognitive impairment~* Drug abuse/dependence~* History of / current psychiatric disorders~* Use of anti-epileptics (e.g. carbamezapine)~* Cushing Disease~* Type 1 diabetes or Type 2 diabetes with medication known to induce hypoglycemia (f.e. Sulfonylurea derivatives~* Current treatment for second malignancy~* Have a significant medical condition (e.g. hepatic, respiratory, or cardiovascular) which, in the opinion of the investigator, may interfere with the interpretation of results and safety or efficacy evaluations.~* A history of frequent hypocortisolism~* Hospitalization during study~* Work in shifts

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- First low dose HC followed by high dose HC (Type: ACTIVE_COMPARATOR): First low dose of hydrocortisone = 0.2-0.3 mg/kg body weight for 10 weeks followed by a high dose of hydrocortisone = 0.4-0.6 mg/kg body weight
- First high dose HC followed by low dose HC (Type: ACTIVE_COMPARATOR): First a high dose of hydrocortisone = 0.4-0.6 mg/kg body weight for 10 weeks followed by a low dose of hydrocortisone = 0.2-0.3 mg/kg body weight

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of OBE2109 in Subjects With Heavy Menstrual Bleeding Associated With Uterine Fibroids

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 5.0

Eligibility Criteria:
Key Inclusion Criteria:~* Premenopausal woman at screening.~* Body Mass Index ≥ 18 kg/m2.~* Menstrual cycles ≥ 21 days and ≤ 40 days.~* Presence of uterine fibroids.~* Heavy menstrual blood loss for each of the 2 menstrual periods assessed at screening using the alkaline hematin method.~Key Exclusion Criteria:~* The subject is pregnant or breast-feeding or is planning a pregnancy within the duration of the treatment period of the study.~* History of uterus surgery that would interfere with the study.~* The subject's condition is so severe that she will require surgery within 6 months regardless of the treatment provided.~* Undiagnosed abnormal uterine bleeding.~* Significant risk of osteoporosis or history of, or known osteoporosis or other metabolic bone disease.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- OBE2109 dose 1 (100mg) + Placebo Add-back (Type: EXPERIMENTAL): None
- OBE2109 dose 1 (100mg) + Add-back (Type: EXPERIMENTAL): None
- OBE2109 dose 2 (200mg) + Placebo Add-back / OBE2109 dose 2 (200 mg) + Add-back (Type: EXPERIMENTAL): None
- OBE2109 dose 2 (200mg) + Add-back (Type: EXPERIMENTAL): None
- Placebo + Placebo Add-back / OBE2109 dose 3 (200mg) + Add-back (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Phase 2, Multicenter, Randomized, Double-Blind, Vehicle Controlled, Parallel-Group, Clinical Study in the Treatment of Acne Vulgaris

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~1. Male or female at least 9 years of age and older.~2. Written and verbal informed consent must be obtained. Subjects less than age of consent must sign an assent for the study and a parent or a legal guardian must sign the informed consent (if subject reaches age of consent during the study they should be re-consented at the next study visit).~3. Subject must have an EGSS of 3 (moderate) or 4 (severe) at the baseline visit.~4. Subjects with a facial acne inflammatory lesion (papules, pustules, and nodules) count no less than 20, but no more than 100.~5. Subjects with a facial acne non-inflammatory lesion (open and closed comedones) count no less than 30, but no more than 150.~6. Subjects with 2 or fewer facial nodules~Exclusion Criteria:~1. Use of an investigational drug or device within 30 days of enrollment or participation in a research study concurrent with this study.~2. Any dermatological conditions on the face that could interfere with clinical evaluations such as acne conglobata, acne fulminans, secondary acne, perioral dermatitis, clinically significant rosacea, gram negative folliculitis, dermatitis, eczema.~3. Any underlying disease(s) or some other dermatological condition of the face that requires the use of interfering topical or systemic therapy or makes evaluations and lesion count inconclusive.~4. Subjects with a facial beard or mustache that could interfere with the study assessments.~5. Subjects with more than 2 facial nodules.~6. Evidence or history of cosmetic-related acne.

- Gender: ALL
- Minimum Age: 9 Years
- Maximum Age: 99 Years
- Healthy Volunteers: f

Study Arms:
- IDP-126 Gel (Type: EXPERIMENTAL): Gel
- IDP-126 Component A (Type: ACTIVE_COMPARATOR): Component A
- IDP-126 Component B (Type: ACTIVE_COMPARATOR): Component B
- IDP-126 Component C (Type: ACTIVE_COMPARATOR): Component C
- IDP-126 Vehicle Gel (Type: PLACEBO_COMPARATOR): Vehicle Gel

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Phase 1/2 Study of SB1518 for the Treatment of Advanced Myeloid Malignancies

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria~* During the dose escalation phase: subjects with histologically confirmed myeloid malignancy who have failed standard therapies or are not candidates for palliative therapies. This includes the following:~  * Subjects with Acute Myelogenous Leukemia (AML)~ * Subjects with Chronic Myelogenous Leukemia (CML) in accelerated phase~ * Subjects with Chronic Myelogenous Leukemia (CML) in blast crisis~ * Subjects with high-risk Myelodysplastic Syndromes (MDS) or Chronic Myelomonocytic Leukemia (CMML)~ * Subjects with Advanced Myelofibrosis (MF)~ * In Phase 2, subjects with CIMF (as well as post ET/PV MF)~* Eastern Cooperative Oncology Group (ECOG) performance status 0-2~* All men of reproductive potential and women of child-bearing potential must agree to practice effective contraception during the entire study period and for one month after the last study treatment, unless documentation of infertility exists. Additionally, women of child-bearing potential must have a negative pregnancy test within 14 days prior to the first dose of study drug~* Able to understand and willing to sign the informed consent form~Exclusion Criteria~* Subjects with Chronic Myelogenous Leukemia (CML) in chronic phase;~* Uncontrolled inter-current illness including, but not limited to, ongoing active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements as judged by treating physician. Subjects receiving antibiotics for infections that are under control may be included in the study;~* Concurrent malignancy, except those subjects with early stage squamous cell carcinoma of the skin, basal cell carcinoma of the skin, or cervical intraepithelial neoplasia are eligible for the study;~* Known HIV-positive (such subjects are at increased risk of lethal infections when treated with potentially marrow-suppressive therapy);~* Known active hepatitis A, B, or C;~* Women who are pregnant or lactating.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Pegfilgrastim as Support to Advanced Breast Cancer Patients Receiving Chemotherapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
* Advanced breast cancer~* 18 years of age or older~* Patients who will be receiving Taxotere (docetaxel) chemotherapy

- Gender: None
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Breast cancer patients receiving docetaxel chemotherapy and placebo.
- Pegfilgrastim (Type: EXPERIMENTAL): Breast cancer patients receiving docetaxel chemotherapy and pegfilgrastim.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Almorexant (ACT 078573) in Adult Subjects With Chronic Primary Insomnia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Adult subjects (18-64 years) with a diagnosis of primary insomnia.~Exclusion Criteria:~* History of any sleep disorder, or any Diagnostic and Statistical Manual of Mental Disorders, 4th edition (DSM-IV) axis I disorder other than primary insomnia.~* Sleep apnea, or restless legs syndrome.~* Daytime napping of more than 1 hour per day.~* Important caffeine consumption, heavy tobacco use, alcohol or drug abuse within 2 years prior to the screening visit.~* Unwillingness to refrain from drugs, over-the-counter or herbal medication having an effect on sleep or behavior.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 64 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): almorexant 200 mg
- 2 (Type: EXPERIMENTAL): almorexant 100 mg
- 3 (Type: PLACEBO_COMPARATOR): Placebo
- 4 (Type: ACTIVE_COMPARATOR): zolpidem 10 mg

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety, Immunogenicity of RTS,S/AS02A, and RTS,S/AS01B Malaria Vaccines in Malaria-experienced Adults.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion criteria:~* Healthy male or female volunteers aged between 18 and 35 years at the time of first vaccination who have given written consent for their participation in the study were included~* If the volunteer is female, she must be of non-childbearing potential, i.e. either surgically sterilized or one year post-menopausal; or, if of childbearing potential, she must be abstinent or have used adequate contraceptive precautions for 30 days prior to vaccination, have a negative pregnancy test and must agree to continue such precautions for two months after completion of the vaccination series~Exclusion criteria:~* If a subject plans to take vaccine not foreseen by the study protocol within 30 days of the first dose of vaccine(s) with the exception of tetanus toxoid will be excluded~* Volunteers with any confirmed or suspected immunosuppressive or immunodeficient conditions~* Family history of congenital or hereditary immunodeficiency~* History of allergic reactions to previous immunizations~* HBsAg positive subjects~* History of splenectomy~* Pregnant or lactating females will be excluded from the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 35 Years
- Healthy Volunteers: t

Study Arms:
- VACC 1 (RTS, S/AS01B) (Type: EXPERIMENTAL): RTS, S/AS01B: 0.5mL dose; 50ug RTS, S antigen, 50ug QS21 and liposomes in phosphate-buffered saline administered intramuscular deltoid of non-dominant arm at 0, 1 and 2 months.
- VACC 2 (RTS, S/AS02A) (Type: EXPERIMENTAL): RTS, S/AS02A: 0.5mL dose; 50ug RTS, S antigen, 50ug QS21 and proprietary oil-water emulsion in phosphate-buffered saline administered intramuscular deltoid of non-dominant arm at 0, 1 and 2 months.
- Rabipur (Rabies) Vaccine (Type: ACTIVE_COMPARATOR): Rabipur (Rabies) Vaccine: 1.0mL dose administered intramuscular deltoid of non-dominant arm at 0, 1 and 2 months.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete